Skip to main content
Clinical Trials/IRCT20170112031891N2
IRCT20170112031891N2
Completed
Phase 3

Investigating the effectiveness of L-arginine in reducing duration of hospitalization and pain intensity of children with sickle cell disease compared to placebo.

Ahvaz University of Medical Sciences0 sites120 target enrollmentStarted: TBDLast updated:

Overview

Phase
Phase 3
Status
Completed
Enrollment
120

Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
3 years to 20 years (—)
Sex
All

Inclusion Criteria

  • Patients affected by sickle cell disease
  • Age 3 to 20 years

Exclusion Criteria

  • liver failure
  • Renal failure
  • Under 5 grams of hemoglobin per deciliter
  • Patients in need of immediate infusion of blood
  • History of hospitalization more than 10 times in the hospital
  • A history of opiate dependence
  • Sensitivity to arginine

Investigators

Similar Trials